Small, stable and robust, VHH offer an attractive construct for incorporation as targeting agents in cell therapies.
VHH can also be easily multimerised to meet a variety of therapeutic needs, enabling refined cell targeting and modes of action while also minimising off-target toxicity. Away from the ectodomain, their small size also permits packaging of more sophisticated intracellular signalling domains, supporting the next generation of cell therapies.
VHH in Cell Therapy
Smaller constructs mean more space for multi-specific targeting modules or next-generation signalling domains.
1. Jayaraman J et al. (2020) Ebiomedicine 58: 102931
2. Lamers CH, et al. (2011) Blood 117(1):72-82
3. Ackaert C et al. (2021) Front. Immunol. 12: 632687
4. Desmyter A et al. (1996) Nat Struct Biol 3(9): 803-811
VHH in CAR-T Resources
VHHs enable multi-specific targeting for Tandem-CAR therapies
In this poster from 7th CAR-TCR Summit in Boston, we discuss the power of VHHs in creating multi-specific ectodomains.
Advantages of using VHH antibodies for CAR engineering
We explain the advantages of VHHs for CAR ectodomain targeting relative to traditional scFvs including size, solubility, and VHHs unique “magic finger” CDR3 domain.
Using synthetic VHH to optimize T-cell mediated immunotherapies
In this webcast, speakers will introduce the unique benefits of the VHH antibodies generated from the LlamdA™ synthetic library and summarize how VHHs can be engineered to tune their binding selectivity and specificity and help optimize the next generation of cell therapies.
Partnerships at Isogenica
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.